Genotype 4, finally cured? Imam Waked Professor of Medicine National Liver Institute

Size: px
Start display at page:

Download "Genotype 4, finally cured? Imam Waked Professor of Medicine National Liver Institute"

Transcription

1 Genotype 4, finally cured? Imam Waked Professor of Medicine National Liver Institute Paris, January 12, 215

2 Disclosures Investigator, speaker, and advisory board member for: Roche, MSD, BMS, Gilead, Janssen, Abbvie Presentation includes use of unlicensed drugs

3 Genotype 4, finally cured? Outline Epidemiology Therapy Historical: PEG-RBV Current: PEG-RBV Triple therapy IFN Free therapy IFN and RBV Free therapy Subtypes The Final Cure?

4 HCV Genotype Distribution Globally HCV a global health challenge with ~15-18 Million chronic HCV infections Genotype 1 is the most prevalent in most countries 4; 15% 5; 1% 6; 2% 1; 47% 3; 22% 2; 14% Genotype 4: 12%-15% (15-18 Million) of total global HCV infection 1. Gower, E., et al., J Hepatol 214; 61:S45 S57; 2. Messina J. et al. Hepatology, 215;61:

5 HCV Genotype Distribution Globally Global Total ~15-18 Million <5, -15, 5-7, South America North America Europe Asia and Australia Million Africa and Middle East Million ~85% G-4 distribution restricted to regions: in Egypt, Central Africa, and the Middle East 1. Gower, E., et al., J Hepatol 214; 61:S45 S57; 2. Messina J. et al. Hepatology, 215;61:

6 Genotype 4 Distribution by Country Africa & Middle East Egypt Palestine Libya Saudi Arabia Equatorial Guinea Gabon Lebanon UAE Central African Republic Syria Jordan Kuwait Iraq Congo Ethiopia G-4 is considered endemic, circulated for generations in restricted regions 1. Gower, E., et al., J Hepatol 214; 61:S45 S57; 2. Messina J. et al. Hepatology, 215;61:

7 Genotype 4 Distribution by Country Europe, Asia, North and South America France Belgium Portugal Spain Netherlands Switzerland Greece Italy Germany Austria HCV G-4 is increasing in Europe due to prevalence in PWID and migration Increasing in France (>1%), Spain (>15% in South Spain) and Italy Ireland Czech Republic United Kingdom Slovakia Norway Georgia Denmark Russia Sweden Belarus Finland Poland Turkey North America Hungary Armenia South America Asia, South Estonia Asia Central Lithuania Asia East 1. Gower, E., et al., J Hepatol 214; 61:S45 S57; 2. Messina J. et al. Hepatology, 215;61: Asselah et al. J Hepatol. 212; 56:527-32; 4. Cifuentes C Et al. Enferm Infecc Microbiol Clin 212; 3:452-7; 5. Sariguzel et al. Clin Lab. 213; 59:143-8 Latvia Asia Southeast

8 Genotype 4, finally cured? Epidemiology Therapy Historical: PEG-RBV Current: PEG-RBV Triple therapy IFN Free therapy IFN and RBV Free therapy Subtypes The Final Cure?

9 AI ASV +DCV SVR4 GT 1 Null Responders Genotype 4 PEG-RBV Therapy Real-World Experience for naive HCV patients (PROPHESYS cohort study, n=7,163) Historically, HCV-G4 was considered to respond to PEGRBV better than G1 but lower than G2 and G3 Virologic response (%) SVR SVR SVR SVR G1 G2 G3 G4 (n = 4,52) (n = 1,25) (n = 1,259) (n = 317) SVR G5/6 (n = 28) Pts with HCV GT4 treated with PegIFNα + RBV for 48 wks Marcellin P, et al. Hepatology 212; 56:

10 DAAs with Efficacy Data for HCV-G4 Drugs Drug Target Protease G4 Approved Simeprevir NS5A Daclatasvir Non-nucleoside Asunaprevir Paritaprevir Phase II and III Effective in G4 Danoprevir Ledipasvir PPI-668 Ombitasvir GS-5816 Beclabuvir NS5B Nucleoside Approved for other genotype Effective in G4 Sofosbuvir

11 PEG-RBV + DAA Triple Therapy for HCV-Genotype 4 DCV 24 wks + PEG-RBV 48 wks Naiive, COMAND ,2 87,5 9,5 8 Patients with SVR 24, % SVR-12 SMV 12 wks + PEG-RBV wks RESTORE DCV 6 mg + alfa/rbv 33, Placebo + alfa/rbv n/n = GT 1 ASN+DCV+PEG-RBV HALLMARK QUAD G1a SVR 12 (%) Patients with SVR24 (%) G1b 1. Moreno, C., et al. J Hepatol, Jenssen D et al. Liver Intl G GT 1a GT 1b GT 4 SOF + PEG-RBV 12 wks NEUTRINO Overall 2 He zode C, et al. Gut, Lawitz, E., et al. N Engl J Med, GT-4 GT-5, GT-6

12 IFN-Free Therapy in Genotype 4 SOF + RBV in Treatment-Naïve and Experienced US Patients of Egyptian Ancestry Randomized, open-label, single-center study conducted in the US of the safety and efficacy of all-oral SOF + RBV in patients of Egyptian ancestry with HCV GT 4, 6 patients Treatmentnaive Naiive SOF+ RBV (n=14) 8 Experienced Treatmentexperienced SOF+ RBV (n=17) SOF + RBV (n=15) Week 24 SOF 4 mg + Weight-based RBV dosing (-12 mg). Male (68%), cirrhosis (23%), HCV RNA (5.7 to 6.1 log1 IU/mL), IL28B non-cc (83%). 12 SVR 12 SOF + RBV (n=14) SOF+RBV well-tolerated for up to 24 weeks of treatment 12 Weeks No discontinuation due to AEs No Grade 4 AEs or lab abnormalities were reported No SOF resistance mutation S282T was found in any patient with virologic failure Ruane P, EASL, 214, P Weeks

13 IFN-Free Therapy in Genotype 4 SOF + RBV in Treatment-Naïve and Experienced Egyptian Patients Naiive Treatmentnaive Treatmentexperienced 8 SOF+ RBV (n=27) 12 SOF 4 mg + Weight-based RBV dosing (-12 mg). Male (67%), cirrhosis (17%), 52% high viral load (>8, IU/ml), IL28B non-cc (81%) wks 24 wks Experienced SOF + RBV (n=27) Week 8 Overall SOF+ RBV (n=25) SOF + RBV (n=24) Randomized, open-label, multi-center study conducted in Egypt of the safety and efficacy of all-oral SOF + RBV in Egyptian patients with HCV GT 4, 13 patients 12 wks 24 wks Naïve patients, with <=F2 Fibrosis, low viral load (<6, IU): % SVR with 12 wks treatment Esmat G. et al. AASLD wks 24 wks

14 IFN- & RBV-Free Therapy in Genotype 4 LED + SOF in Treatment-Naïve and Experienced Patients (SYNERGY) Phase II trial of LDV/SOF for 12 weeks in GT4-infected patients, including 43% with advanced fibrosis LDV/SOF (n=21) LDV = 9 mg12 wks SOF = 4 mg 24 wks % Treatment experienced 1% advanced fibrosis 33% compensated cirrhosis One person stopped treatment after the first dose. Regimen safe and well tolerated, no deaths, SAEs or grade 4 laboratory abnormalities. Most common AEs: fatigue, diarrhea and nausea. Kapoor R, et al. Hepatology 214;6(Suppl):91A.

15 IFN- & RBV-Free Therapy in Genotype 4 ASV + BCV + DCV in Treatment-Naïve Patients HCV GT4 treatment-naive adults, including those with compensated cirrhosis received triple therapy of ASV, BCV, and DCV for 12 weeks ASV + BCV 75 mg + DCV (n=11) ASV + BCV 15 mg + DCV (n=1) Response (%) 24 wks 12 wks 8 Two patients had missing data at post-treatment Week 12 but subsequently achieved SVR No patient had on-treatment virologic failure or experienced relapse n N Week EOT Hassanein T, et al. J Hepatol. 215; doi: SVR

16 IFN- & RBV-Free Therapy in Genotype 4 OMB + PAR/r +/- RBV in Treatment-Naive Patients (PEARL-I) An open-label Phase 2b study (PEARL-I) evaluated the safety and efficacy of 2DAAs with or without RBV for 12 weeks for the treatment of HCV GT4-infected patients Group I N=44 G4 PAR/r + OMB Naiive SVR12 9,9 8 Group 2 PAR/r + OMB N=44 G1b Naiive Group 3 PAR/r + OMB N=4 G1b Null Responders Group 4 PAR/r + OMB + RBV N=42 G4 Naiive Group 5 N=44 G4 PAR/r + OMB Partial/Null Responders, Relapsers Group 6 N=49 G4 PAR/r + OMB + RBV Partial/Null Responders, Relapsers Pol S, et al. Hepatology 214; 6: 1129A 1

17 Genotype 4, finally cured? Epidemiology Therapy Historical: PEG-RBV Current: PEG-RBV Triple therapy IFN Free therapy IFN and RBV Free therapy Subtypes The Final Cure?

18 Genotype 4 Subtypes Egypt 4a Syria 4a Saudi Arabia 4a, 4d Yemen 4a Response to PEG-RBV 6 5 SVR% Subtypes (4a-4w) Cameroun 4f, 4e Congo 4b, 4c Subtypes responded differently to PEG-RBV therapy Impact of G4 subtype on response to DAA still not known 2 1 4a non 4a 1. Smith DB. et al. Hepatology. 214;59: Gower, E., et al., J Hepatol 214; 61:S45 S57; 3. Messina J. et al. Hepatology, 215;61: Roulot D et al. J Viral Hepat Moucari R et al. Gut 29

19 Genotype 4, finally cured? Epidemiology Therapy Historical: PEG-RBV Current: PEG-RBV Triple therapy IFN Free therapy IFN and RBV Free therapy Subtypes The Final Cure?

20 Summary of Currently Available Therapies Triple Therapy with PEG-RBV Interferon Free 87 <5, % S VR 12 9,9-15, 5-7, Resource Limited Settings? 95 South America North America Europe Million Asia and Australia Africa and Middle East Million 6-8 Million ~85% ~45% Egypt 6-7 Million ~4% 1. He zode C, et al. Gut, Ruane P et al. EASL 214, 2. Moreno, C., et al. J Hepatol, 214, 3. Lawitz, E., et al. N Engl J Med, Esmat G el al. AASLD 214, 6. Kapoor et al. AASLD 214, 7. Pol S. et al. Hepatology 214

21 The Final Cure? Resource Limited Settings? The Egypt Example % S VR 12 Currently: SOF based therapy SOF-PEG-RBV 12 wks for IFN eligible patients SOF-RBV 24 wks for IFN ineligible patients Total estimate 6-7 Mill 95% G4 Gilead access program reduced cost drastically National treatment program started October 214 NCCVH Egypt, Data on file , registered for 9,9 evaluation 4, F3 and F4 selected for treatment 15, started treatment, 33% SOF+PEG-RBV 67% SOF+RBV 95 Of those who reached wk4, 99% >2 log1 reduction in viral load 82% RNA <LLQ (<15 IU/ml) 81.3% SOF-RBV

22 The Final Cure? Resource Limited Settings? The Egypt Example Negotiating and evaluating IFN & RBV free therapies for G4: LED-SOF, SIM-SOF, DCV-SOF, OMB-PAR/r National HCV Control Target: Treat 3-35, a year, 9% SVR, 1-15 yrs # Cirrhosis Total Infected 6-95% % 76 Annual HCV-related Mortality HCC % HCC: 17, cases Prevented between 215 and 23 Mortality: 26, cases prevented between 215 and NCCVH data Waked I, et al. Arab J Gastro

23 Summary HCV G4 is common, mainly in resource limited settings in Africa and the Middle East Increasing in Western Europe Egypt has 4% of global HCV-G4 patients Current therapies have high cure rates All oral therapies with > 95% SVR and short duration becoming available, promising complete cure With affordable prices, HCV-G4 will be cured, even in the resource limited settings where it is most prevalent 2

24 Merci Thank You ش ك را

How to optimize treatment for HCV Genotype 4

How to optimize treatment for HCV Genotype 4 How to optimize treatment for HCV Genotype 4 Paris Hepatitis Conference Pr Tarik Asselah 14 janvier 2014 MD, PhD Service d Hépatologie & INSERM U773 University Paris Diderot Hôpital Beaujon, Clichy tarik.asselah@bjn.aphp.fr

More information

Access to HCV treatment in Egypt

Access to HCV treatment in Egypt Access to HCV treatment in Egypt Prof. Gamal Esmat Prof. Hepatology &Vice President of Cairo University, Egypt Member of WHO Strategic Committee for Viral Hepatitis www.gamalesmat.com Global genotype distribution

More information

Access to treatment and disease burden

Access to treatment and disease burden Access to treatment and disease burden Robert Flisiak Department of Infectious Diseases and Hepatology Medical University in Białystok, Poland Moulin de Vernègues, 27-29 August 2015 Disclosures Advisor

More information

HCV treatment options in clinical practice. Current treatment options for HCV-G4

HCV treatment options in clinical practice. Current treatment options for HCV-G4 HCV treatment options in clinical practice Current treatment options for HCV-G4 C. Triantos Gastroenterology Department University Hospital of Patras Conflicts of interest Speaker and research/travel grants

More information

Treatments of Genotype 2, 3,and 4: Now and in the future

Treatments of Genotype 2, 3,and 4: Now and in the future Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve

More information

Real-life results of triple therapy with the combination of sofosbuvir-pegylated interferon-ribavirin for Egyptian patients with hepatitis C

Real-life results of triple therapy with the combination of sofosbuvir-pegylated interferon-ribavirin for Egyptian patients with hepatitis C Real-life results of triple therapy with the combination of sofosbuvir-pegylated interferon-ribavirin for Egyptian patients with hepatitis C Prof. Gamal Esmat Prof. Hepatology & Vice President of Cairo

More information

The Egyptian Plan to Cure HCV

The Egyptian Plan to Cure HCV The Egyptian Plan to Cure HCV Gamal Esmat Professor of Endemic Medicine & Hepatology Vice President of Cairo University for Graduate Studies and Research Disclosure Advisory Committee Board Member : MSD,

More information

Treating HCV Genotype 2 & 3

Treating HCV Genotype 2 & 3 Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy

More information

Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov

Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients

More information

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor

More information

Rome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING

Rome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN

More information

IFN-free therapy in naïve HCV GT1 patients

IFN-free therapy in naïve HCV GT1 patients IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,

More information

Evolution of Therapy in HCV

Evolution of Therapy in HCV Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR

More information

Why make this statement?

Why make this statement? HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed

More information

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate

More information

Update on chronic hepatitis C treatment: current trends, new challenges, what next?

Update on chronic hepatitis C treatment: current trends, new challenges, what next? Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15

More information

Update in the Management of Hepatitis C: What Does the Future Hold

Update in the Management of Hepatitis C: What Does the Future Hold Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana

More information

VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES

VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade

More information

HCV therapy : Clinical case

HCV therapy : Clinical case HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah

More information

SVR Updates from the 2013 EASL

SVR Updates from the 2013 EASL Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations

More information

Hepatitis C Emerging Treatment Paradigms

Hepatitis C Emerging Treatment Paradigms Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,

More information

Clinical Management: Treatment of HCV Mono-infection

Clinical Management: Treatment of HCV Mono-infection Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry

More information

HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London

HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown

More information

How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France

How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding

More information

Hepatitis C Treatment 2014

Hepatitis C Treatment 2014 Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype

More information

Latest Treatment Updates for GT 2 and GT 3 Patients

Latest Treatment Updates for GT 2 and GT 3 Patients Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of

More information

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370: Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV

More information

Tough Cases in HIV/HCV Coinfection

Tough Cases in HIV/HCV Coinfection NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014

More information

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on

More information

Ledipasvir-Sofosbuvir (Harvoni)

Ledipasvir-Sofosbuvir (Harvoni) HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical

More information

Failure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016

Failure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016 Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16 Disclosures Board member for : Schering-Plough,

More information

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients 5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,

More information

Experience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona

Experience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir

More information

The HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)

The HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1) Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell

More information

Available Hepatitis Information: how can this be used to convince decision makers and potential funders

Available Hepatitis Information: how can this be used to convince decision makers and potential funders Available Hepatitis Information: how can this be used to convince decision makers and potential funders H. Razavi June 6, 2015 Viral Hepatitis Prevention Board Meeting, London, UK 56 June 2015 It s not

More information

CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA

CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and

More information

Associate Professor of Medicine University of Chicago

Associate Professor of Medicine University of Chicago Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death

More information

HCV In 2015: Maximizing SVR

HCV In 2015: Maximizing SVR HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last

More information

Update on the Treatment of HCV

Update on the Treatment of HCV Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure

More information

Antiviral treatment in HCV cirrhotic patients on waiting list

Antiviral treatment in HCV cirrhotic patients on waiting list Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory

More information

TREATMENT OF GENOTYPE 2

TREATMENT OF GENOTYPE 2 Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,

More information

Treatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona

Treatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir

More information

Disclosures. I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences.

Disclosures. I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences. Disclosures I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences. Chronic Hepatitis C Prof CL Lai University Department of

More information

Future strategies with new DAAs

Future strategies with new DAAs Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks

More information

Transformation of Chronic Hepatitis C Treatment

Transformation of Chronic Hepatitis C Treatment Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence

More information

HALLMARK-DUAL Study. Daclatasvir + Asunaprevir in Genotype 1b. Hepatitis. Treatment-Naïve and Treatment-Experienced

HALLMARK-DUAL Study. Daclatasvir + Asunaprevir in Genotype 1b. Hepatitis. Treatment-Naïve and Treatment-Experienced Phase 3 Treatment-Naïve and Treatment-Experienced Daclatasvir + Asunaprevir in Genotype 1b HALLMARK-DUAL Study Manns M, et al. Lancet. 2014;384:1597-605. Daclatasvir + Asunaprevir for HCV GT 1b HALLMARK-DUAL:

More information

Baseline and acquired viral resistance to DAAs: how to test and manage

Baseline and acquired viral resistance to DAAs: how to test and manage Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline

More information

Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College

Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus

More information

8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV

8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology

More information

New developments in HCV research and their implications for front-line practice

New developments in HCV research and their implications for front-line practice New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013

More information

Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.

Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours. Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship

More information

Can we afford to Cure all HIV-HCV Co-infected Patients of HCV?

Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr

More information

Ed Gane NZ Liver Transplant Unit Auckland City Hospital

Ed Gane NZ Liver Transplant Unit Auckland City Hospital Clinical Management of Hepatitis C Patients Treat Now or Wait Ed Gane NZ Liver Transplant Unit Auckland City Hospital SVR24 rates with PEG/RBV by HCV genotype Data from the real-world PROPHESYS cohort

More information

Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos

Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology

More information

Initial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona

Initial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives

More information

The Changing World of Hepatitis C

The Changing World of Hepatitis C The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures

More information

Hepatitis C Resistance Associated Variants (RAVs)

Hepatitis C Resistance Associated Variants (RAVs) Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure

More information

Pivotal New England Journal of Medicine papers 2014 Phase 3 Trial data

Pivotal New England Journal of Medicine papers 2014 Phase 3 Trial data 4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:

More information

The Dawn of a New Era: Hepatitis C

The Dawn of a New Era: Hepatitis C The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should

More information

Progression of the disease. Heiner Wedemeyer

Progression of the disease. Heiner Wedemeyer Progression of the disease Heiner Wedemeyer Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Abvie, Biolex, BMS, Boehringer Ingelheim, Eiger, Gilead, ITS, JJ/Janssen-Cilag, Medgenics,

More information

Treatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy

Treatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy Treatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy antonio.craxi@unipa.it Ad Board and grants: Abbvie, Achillion, BristolMyers Squibb,

More information

HCV-G3: Sofosbuvir with ledipasvir or daclatasvir?

HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic

More information

NS5A inhibitors: ideal candidates for combination?

NS5A inhibitors: ideal candidates for combination? NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang

More information

Dr. Siddharth Srivastava

Dr. Siddharth Srivastava Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.

More information

EASL and The Future of HCV Treatment

EASL and The Future of HCV Treatment EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine

More information

IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?

IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University

More information

Treatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble

Treatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989

More information

HCV Management in Decompensated Cirrhosis: Current Therapies

HCV Management in Decompensated Cirrhosis: Current Therapies Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu

More information

Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4

Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4 Phase 3 Treatment Experienced Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4 Bourlière M, et al. N Engl J Med. 217;376:2134-46. POLARIS-4: Study Features POLARIS-4 Trial Design:

More information

Introduction. The ELECTRON Trial

Introduction. The ELECTRON Trial 63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver

More information

Treatment of HCV in 2016

Treatment of HCV in 2016 5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,

More information

HCV Treatment of Genotype 1: Now and in the Future

HCV Treatment of Genotype 1: Now and in the Future HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program

More information

Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany

Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:

More information

2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients

2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients 2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director

More information

Interferon-based and interferon-free new treatment options

Interferon-based and interferon-free new treatment options Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt

More information

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,

More information

Need to Assess HCV Resistance to DAAs: Is it Useful and When?

Need to Assess HCV Resistance to DAAs: Is it Useful and When? Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital

More information

Overcoming barriers to access to hepatitis C treatment in a rapidly changing landscape

Overcoming barriers to access to hepatitis C treatment in a rapidly changing landscape Overcoming barriers to access to hepatitis C treatment in a rapidly changing landscape HIV/AIDS Department and Global Hepatitis Programme Dr. Stefan Wiktor Outline Global Hepatitis Strategy New HCV treatment

More information

HCV treatment in Australia: a new role for GPs

HCV treatment in Australia: a new role for GPs Disclosures HCV treatment in Australia: a new role for GPs Dr David Iser The Alfred & St. Vincent s Hospitals 15 th October 2016 I have received honoraria for presentations and/or consultancies from: AbbVie

More information

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled

More information

Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.

Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours. Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship

More information

Treatment of Unique Populations Raymond T. Chung, MD

Treatment of Unique Populations Raymond T. Chung, MD Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research

More information

Will difficult-to-treat patients remain difficultto-treat. generation of treatments?

Will difficult-to-treat patients remain difficultto-treat. generation of treatments? Will difficult-to-treat patients remain difficultto-treat with the new generation of treatments? Jordan J Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University

More information

Treating HCV After Liver Transplantation: What are the Treatment Options?

Treating HCV After Liver Transplantation: What are the Treatment Options? 4 th OPTIMIZE WORKSHOP USING DAAs IN PATIENTS WITH CIRRHOSIS AND LIVER RECIPIENTS Treating HCV After Liver Transplantation: What are the Treatment Options? Maria Carlota Londoño, MD Liver Unit, Hospital

More information

Shorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore

Shorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution

More information

Protease inhibitor based triple therapy in treatment experienced patients

Protease inhibitor based triple therapy in treatment experienced patients Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber

More information

DAAs in the era of decompensated liver disease. Piero L. Almasio University of Palermo

DAAs in the era of decompensated liver disease. Piero L. Almasio University of Palermo DAAs in the era of decompensated liver disease Piero L. Almasio University of Palermo piero.almasio@unipa.it HCV therapy in the era of interferon based therapy Priority Compensated cirrhosis Decompensated

More information

Feeling right at home

Feeling right at home Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements

More information

47 th Annual Meeting AISF

47 th Annual Meeting AISF 47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,

More information

Hepatitis C in Special Populations

Hepatitis C in Special Populations Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health

More information

HCV Resistance Associated variants: impact on chronic hepatitis C treatment

HCV Resistance Associated variants: impact on chronic hepatitis C treatment HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only

More information

New Therapeutic Strategies: Polymerase Inhibitors

New Therapeutic Strategies: Polymerase Inhibitors New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2

More information

A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran

A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs

More information

Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London

Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London IFN free therapy Disclosures I have received personal and institutional funding from companies that sell drug

More information

Recent Management of Chronic Hepatitis C

Recent Management of Chronic Hepatitis C 2014-6-12 KASL Liver Week 2014 Recent Management of Chronic Hepatitis C Jae-Jun Shim Kyung Hee University School of Medicine, Seoul, Korea Meeting today Cost and future perspectives Guidelines Recent guidelines

More information

Highlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases

Highlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with

More information

Individual Optmizaton of therapy. Graham R Foster Professor of Hepatology QMUL

Individual Optmizaton of therapy. Graham R Foster Professor of Hepatology QMUL Individual Optmizaton of therapy Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novarts, Springbank,

More information

THE LIVER MEETING 2014:

THE LIVER MEETING 2014: THE LIVER MEETING 2014: Summary of presentations from the 65 th Annual Liver Meeting of the American Association for the of Liver Diseases (AASLD), held in Boston, Massachusetts, USA, on 7 th -11 th November

More information

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1)

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Goals for Hepatitis C Therapy Compared to PegIFN/RBV, new products should offer: Improved efficacy Efficacy in all patient types including

More information

Special developments in the management of Hepatitis C. Disclosures

Special developments in the management of Hepatitis C. Disclosures Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org

More information